TY - JOUR
T1 - Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063)
T2 - A phase 2, single-arm trial
AU - Rizvi, Naiyer A.
AU - Mazières, Julien
AU - Planchard, David
AU - Stinchcombe, Thomas E.
AU - Dy, Grace K.
AU - Antonia, Scott J.
AU - Horn, Leora
AU - Lena, Hervé
AU - Minenza, Elisa
AU - Mennecier, Bertrand
AU - Otterson, Gregory A.
AU - Campos, Luis T.
AU - Gandara, David R.
AU - Levy, Benjamin P.
AU - Nair, Suresh G.
AU - Zalcman, Gérard
AU - Wolf, Jürgen
AU - Souquet, Pierre Jean
AU - Baldini, Editta
AU - Cappuzzo, Federico
AU - Chouaid, Christos
AU - Dowlati, Afshin
AU - Sanborn, Rachel
AU - Lopez-Chavez, Ariel
AU - Grohe, Christian
AU - Huber, Rudolf M.
AU - Harbison, Christopher T.
AU - Baudelet, Christine
AU - Lestini, Brian J.
AU - Ramalingam, Suresh S.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background: Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer. Methods: We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759. Findings: Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease. Interpretation: Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment. Funding: Bristol-Myers Squibb.
AB - Background: Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer. Methods: We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759. Findings: Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease. Interpretation: Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment. Funding: Bristol-Myers Squibb.
UR - http://www.scopus.com/inward/record.url?scp=84924901863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924901863&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(15)70054-9
DO - 10.1016/S1470-2045(15)70054-9
M3 - Article
C2 - 25704439
AN - SCOPUS:84924901863
SN - 1470-2045
VL - 16
SP - 257
EP - 265
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 3
ER -